BioNTech 2026년 4월 18일 BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily 원문